Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
**Alaquin** is a brand name for a topical combination medication containing **clioquinol** (also known as iodochlorhydroxyquin, 1.25-3%) and **hydrocortisone** (1%, a mild corticosteroid), used to treat inflammatory skin conditions accompanied by fungal or bacterial infections, such as eczema, ringworm, athlete's foot, and jock itch. Clioquinol acts as an anti-infective agent with antifungal and antibacterial properties by preventing microbial growth, while hydrocortisone reduces swelling, redness, and itching through anti-inflammatory effects. It is manufactured by companies including Primus Pharmaceuticals and Sonar Products (discontinued in the US), or Crown Laboratories; apply thinly to affected skin 2-4 times daily, avoiding eyes, mucous membranes, and long-term use due to risks like skin thinning or staining. Not for viral infections like herpes or tuberculosis of the skin; safe for children over 2 years under medical supervision.[2][3][10]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Alaquin.